Oragenics appoints Dr John Bonfiglio
This article was originally published in Scrip
Oragenics, a biopharmaceutical company has appointed Dr John Bonfiglio president and CEO, as well as appointing him to the board of directors. Dr Bonfiglio most recently served as president, CEO and director for Transdel Pharmaceuticals. He has also been CEO of Argos Therapeutics, the Immune Response Corporation and Peregrine Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.